石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

交易中 08-13 11:38:13

9.210

+0.535

+6.17%

最高9.220	最低8.580	成交量6,247万
今开8.615	昨收8.675	日振幅7.38%
总市值1,061亿	流通市值1,061亿	总股本115.22亿
成交额5.62亿	换手率0.54%	流通股本115.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":9.21,"timestamp":1786592291757,"preClose":8.675,"halted":0,"volume":62474622,"delay":0,"changeRate":0.06167146974063402,"floatShares":11522000000,"shares":11522000000,"eps":0.39526677652487113,"marketStatus":"交易中","change":0.535,"latestTime":"08-13 11:38:13","open":8.615,"high":9.22,"low":8.58,"amount":561942388,"amplitude":0.073775,"askPrice":9.21,"askSize":6000,"bidPrice":9.205,"bidSize":40000,"shortable":3,"etf":0,"ttmEps":0.33264874872289835,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1786593600000},"marketStatusCode":2,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":8.675,"dividendRate":0.032911,"openAndCloseTimeList":[[1786584600000,1786593600000],[1786597200000,1786608000000]],"volumeRatio":2.344345,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.544,"impliedVolPercentile":0.5592},"requestUrl":"/m/hq/s/01093/tweets","defaultTab":"tweets","newsList":[{"id":"2659577187","title":"港股异动 | 石药集团(01093.HK)涨近4% 收到阿斯利康3000万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2659577187","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659577187?lang=zh_cn&edition=full","pubTime":"2026-08-13 10:55","pubTimestamp":1786589707,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0067412154.USD","LU0326950275.SGD","LU2039709279.SGD","IE0008368742.USD","LU1960683339.HKD","LU1152091168.USD","01093","LU1152091754.HKD","LU1328277881.USD","LU1008478684.HKD","BK1515","LU1226288170.HKD","HK0000165453.HKD","LU1226288253.USD","SG9999004220.SGD","LU1951186391.HKD","LU0314109678.HKD","BK1191","IE00B031HY20.USD","IE0008369823.USD","LU1226287792.SGD","LU0315179316.USD","LU0501845795.SGD","IE00B543WZ88.USD","KURE","LU1226287529.USD","LU0880133367.SGD","LU1813983027.USD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","LU1226287875.USD","LU1993786604.SGD","LU0140636845.USD","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","BK1521","LU1807302812.USD","LU0072913022.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109899580","title":"异动解读｜石药集团盘中上涨3.57%，阿斯利康siRNA合作3000万美元首付款到账","url":"https://stock-news.laohu8.com/highlight/detail?id=1109899580","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109899580?lang=zh_cn&edition=full","pubTime":"2026-08-13 09:41","pubTimestamp":1786585276,"startTime":"0","endTime":"0","summary":"8月13日，石药集团盘中上涨3.57%，报8.985港元，成交额1.01亿港元。消息面上，公司8月12日公告已收到阿斯利康根据siRNA药物合作协议支付的3000万美元首付款，标志着双方聚焦肝外靶向递送平台的战略合作正式进入付款阶段。叠加8月5日已收到的1000万美元里程碑付款及合资建厂协议，阿斯利康合作持续深化。公司将于8月20日披露中期业绩，市场预期上半年净利润同比增长超131%，花旗维持\"买入\"评级，目标价11.5港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134247130","title":"财报前瞻｜石药集团本季营收预计增25.43%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1134247130","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134247130?lang=zh_cn&edition=full","pubTime":"2026-08-13 08:16","pubTimestamp":1786580161,"startTime":"0","endTime":"0","summary":"石药集团将于2026年08月20日披露中期业绩，市场目光聚焦合作变现与盈利修复进度。市场一致预期本季度石药集团营收约为96.51亿元，调整后每股收益约0.26元，息税前利润约为41.87亿元。公司收入结构以成药为核心，上季度成药实现52.24亿元、占比80.81%，维生素C与功能食品分别贡献4.95亿元与4.71亿元，结构稳定度较高。单季净利润环比增长131.92%，经营动能边际改善迹象出现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜石药集团本季营收预计增25.43%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658707129","title":"石药集团(01093)：2018年股份奖励计划受托人变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2658707129","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658707129?lang=zh_cn&edition=full","pubTime":"2026-08-12 21:15","pubTimestamp":1786540533,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，根据计划规则，2018年股份奖励计划的受托人(受托人)变更将自2026年8月12日起生效。本公司将委聘中银国际信托( 香港 )有限公司(中银国际信托)作为受托人，以取代中银国际英国保诚信托有限公司(中银国际英国保诚)，而本公司与中银国际信托将订立经修订及重列的信托契约，以落实有关变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","LU1152091754.HKD","LU1993786604.SGD","01093","LU0315179316.USD","IE00BZ08YT58.USD","LU1226288253.USD","LU1226287529.USD","IE00BZ08YR35.GBP","HK0000165453.HKD","LU1152091168.USD","LU2039709279.SGD","IE0008368742.USD","LU1951186391.HKD","LU1960683339.HKD","LU0072913022.USD","BK1515","BK1521","LU0314109678.HKD","LU1226287792.SGD","LU1807302812.USD","LU0140636845.USD","LU1226287875.USD","LU1226288170.HKD","SG9999004220.SGD","KURE","IE00B031HY20.USD","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","LU1008478684.HKD","LU0880133367.SGD","LU1328277881.USD","LU0067412154.USD","LU0501845795.SGD","LU0326950275.SGD","LU1813983027.USD","IE0008369823.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188754102","title":"石药集团与阿斯利康siRNA合作进入付款阶段 3,000万美元首付款到账","url":"https://stock-news.laohu8.com/highlight/detail?id=1188754102","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188754102?lang=zh_cn&edition=full","pubTime":"2026-08-12 20:21","pubTimestamp":1786537271,"startTime":"0","endTime":"0","summary":"2026年8月12日，石药集团有限公司（01093）发布自愿公告称，公司已根据与阿斯利康在2026年7月签订的合作、选择权及授权协议，收到对方支付的3,000万美元首付款。\\n\\n根据此前7月2日的公告，双方的合作聚焦于利用石药集团专有的siRNA药物发现平台及肝外靶向递送平台，共同开发新型小核酸候选药物。本次3,000万美元的首付款到账，标志着该战略研发合作的推进。\\n\\n公告同时提示，相关授权产品在开发、生产及商业化过程中仍存在不确定性。公司股东及潜在投资者在买卖公司证券时需审慎行事。石药集团表示，如协议后续出现重大进展，将按规定及时披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658797270","title":"石药集团(01093.HK)收到与阿斯利康就siRNA药物开发订立的合作、选择权及授权协议项下3000万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2658797270","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658797270?lang=zh_cn&edition=full","pubTime":"2026-08-12 20:19","pubTimestamp":1786537187,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["KURE","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1960683339.HKD","BK1515","LU0314109678.HKD","LU1951186391.HKD","01093","LU1328277881.USD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU1008478684.HKD","IE00B543WZ88.USD","LU0140636845.USD","LU1226287529.USD","LU1226287792.SGD","LU1813983027.USD","LU0501845795.SGD","LU1993786604.SGD","IE00BZ08YR35.GBP","BK1521","HK0000165453.HKD","LU0067412154.USD","LU0315179316.USD","IE0008369823.USD","IE00B031HY20.USD","LU1807302812.USD","BK1191","LU1152091168.USD","LU2039709279.SGD","LU0326950275.SGD","LU0880133367.SGD","LU1226287875.USD","IE0008368742.USD","LU0072913022.USD","SG9999004220.SGD","LU1226288253.USD","LU1226288170.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120259263","title":"石药集团：与阿斯利康合作获3000万美元预付款，2026年8月12日到账","url":"https://stock-news.laohu8.com/highlight/detail?id=1120259263","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120259263?lang=zh_cn&edition=full","pubTime":"2026-08-12 20:18","pubTimestamp":1786537091,"startTime":"0","endTime":"0","summary":"石药集团（CSPC PHARMA）宣布，根据双方签署的合作协议，公司已于2026年8月12日收到来自阿斯利康（AstraZeneca）的3000万美元首期付款。这笔款项标志着合作正式启动，彰显了石药集团在药物研发领域的国际认可度。通过此次合作，石药集团不仅获得了可观的财务支持，更打开了全球医药市场的新通道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0501845795.SGD","IE0008368742.USD","LU1226288253.USD","LU1152091754.HKD","LU0880133367.SGD","IE00B031HY20.USD","LU1951186391.HKD","BK1515","IE0008369823.USD","LU1008478684.HKD","LU0315179316.USD","LU1813983027.USD","IE00BZ08YR35.GBP","LU1993786604.SGD","IE00BZ08YT58.USD","LU2039709279.SGD","SG9999004220.SGD","LU1328277881.USD","HK0000165453.HKD","LU0314109678.HKD","LU1226287792.SGD","IE00B543WZ88.USD","LU0140636845.USD","LU1960683339.HKD","BK1191","BK1521","LU1226287875.USD","LU1226287529.USD","01093","IE00B5MMRT66.SGD","LU1807302812.USD","LU1226288170.HKD","IE00BZ08YS42.EUR","LU0072913022.USD","KURE","LU1152091168.USD","LU0067412154.USD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990023","title":"石药集团：SYS6063用于治疗SLE的Ⅰ期临床试验在中国首家中心正式启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990023","media":"第一财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658990023?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:17","pubTimestamp":1786450635,"startTime":"0","endTime":"0","summary":"【石药集团：SYS6063用于治疗SLE的Ⅰ期临床试验在中国首家中心正式启动】石药集团在港交所公告，公司开发的SYS6063用于治疗复发难治性系统性红斑狼疮（SLE）的Ⅰ期临床试验已在中国首家中心正式启动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113838106386.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113838106386.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000165453.HKD","LU1226288170.HKD","SG9999004220.SGD","KURE","LU1226287875.USD","IE00BZ08YT58.USD","LU0072913022.USD","IBBJ","IBBQ","LU0501845795.SGD","SLE","IE0008369823.USD","IE00B031HY20.USD","BK1521","IE00BZ08YR35.GBP","LU0140636845.USD","LU0880133367.SGD","01093","LU1813983027.USD","LU1226287529.USD","LU1008478684.HKD","LU0314109678.HKD","LU1226288253.USD","LU1951186391.HKD","MDTX","IE00BZ08YS42.EUR","LU1152091754.HKD","LU1960683339.HKD","PSYK","LU1328277881.USD","LU0067412154.USD","LU0315179316.USD","BMED","BK1191","BK4077","LU2039709279.SGD","IE00B5MMRT66.SGD","BK1515","LU1993786604.SGD","IE0008368742.USD","LU1152091168.USD","LU1226287792.SGD","LU1807302812.USD","LU0326950275.SGD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179273972","title":"石药集团（01093）全球首款LNP-mRNA CAR-T候选药SYS 6063启动中国首例复难治性系统性红斑狼疮Ⅰ期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=1179273972","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179273972?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:06","pubTimestamp":1786449971,"startTime":"0","endTime":"0","summary":"2026年8月11日，石药集团有限公司公告，其自主研发的SYS 6063用于治疗复发难治性系统性红斑狼疮的Ⅰ期临床试验已在中国首家中心正式启动。该研究为单臂、开放、两阶段、多中心临床试验，旨在评估SYS 6063在SLE患者中的安全性、耐受性、有效性、药代动力学及免疫原性。目前受试者招募与筛选工作正在进行中。目前全球尚无CAR-T疗法获批用于治疗SLE。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189392087","title":"石药集团启动SYS6063用于中国难治性系统性红斑狼疮的I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1189392087","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189392087?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:03","pubTimestamp":1786449807,"startTime":"0","endTime":"0","summary":"石药集团正式宣布，其自主研发的候选药物SYS6063已在中国获批开展I期临床试验。该试验旨在评估SYS6063针对复发或难治性系统性红斑狼疮（SLE）患者的安全性与初步疗效。这一重要进展标志着石药集团在自身免疫性疾病领域的创新研发迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287792.SGD","LU1152091754.HKD","IE00B543WZ88.USD","LU2039709279.SGD","SG9999004220.SGD","LU0072913022.USD","LU0315179316.USD","IE00B5MMRT66.SGD","IE0008368742.USD","LU0314109678.HKD","LU1226288170.HKD","LU0067412154.USD","LU1951186391.HKD","LU1226288253.USD","IE00BZ08YS42.EUR","LU1226287875.USD","LU1008478684.HKD","LU1328277881.USD","KURE","LU0880133367.SGD","BK1515","LU1152091168.USD","BK1521","IE00BZ08YR35.GBP","LU1993786604.SGD","IE00BZ08YT58.USD","BK1191","IE0008369823.USD","LU1813983027.USD","LU1960683339.HKD","HK0000165453.HKD","LU1807302812.USD","LU0501845795.SGD","IE00B031HY20.USD","LU0326950275.SGD","LU1226287529.USD","01093","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658369969","title":"创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658369969","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658369969?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:15","pubTimestamp":1786418137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念持续走强，截至发稿，金斯瑞生物科技 涨6.87%，再鼎医药涨5.51%，同源康医药-B涨4.81%，晶泰控股涨3.94%，药明合联涨3.92%，翰森制药涨3.76%，亚盛医药涨3.63%，百济神州涨3.38%，药明康德涨3.03%，诺诚健华涨2.83%，石药集团涨2.78%。国元国际证券亦表示，出海交易量价齐升，中国创新药全球地位持续提升。中国创新药出海持续超预期，上半年997亿美元的交易总额和全球TOP10中独占8席的成绩，充分验证了中国创新药资产的全球竞争力。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","IBBQ","LU1226288170.HKD","LU2328871848.SGD","01548","BK1588","09688","06855","BK1583","LU0880133367.SGD","HK0000320223.HKD","HK0000306685.HKD","LU0315179316.USD","LU1226287875.USD","LNGR","02228","01093","09969","LU2488822045.USD","KURE","IE00BZ08YS42.EUR","LU1152091168.USD","IE00B031HY20.USD","02359","LU1813983027.USD","LU2039709279.SGD","02268","02410","BK1521","LU1993786604.SGD","LU0072913022.USD","IE00BZ08YR35.GBP","BK1500","BK1617","LU0326950275.SGD","LU2125910500.SGD","03692","LU2242644610.SGD","IE00B543WZ88.USD","159992","IE00BZ08YT58.USD","LU1226287792.SGD","06160","BK1576","IE00B5MMRT66.SGD","LU1303224171.USD","LU1951186391.HKD","BK1515","MEDX","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101288572","title":"石药集团（01093）将于2026年8月20日审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1101288572","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101288572?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:11","pubTimestamp":1786360303,"startTime":"0","endTime":"0","summary":"石药集团有限公司（01093）8月10日公告，公司董事会已定于2026年8月20日（星期四）召开会议，审议并批准截至2026年6月30日止六个月的未经审计中期业绩。董事会名单包括执行董事蔡东晨、蔡磊、魏青杰、张翠龙、王振国、李春雷、姚兵、蔡鑫、陈卫平、屈志勇及张翊维；以及独立非执行董事王波、CHEN Chuan、王宏广、欧振国、罗卓坚及李泉。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190651059","title":"石药集团（01093）：猴痘mRNA疫苗SYS 6037获FDA临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1190651059","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190651059?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:05","pubTimestamp":1786359944,"startTime":"0","endTime":"0","summary":"2026年8月10日，石药集团发布自愿公告称，公司与中国科学院微生物研究所合作开发的预防用生物制品1类新药SYS 6037注射液已获美国食品药品监督管理局批准在美国开展临床试验。SYS 6037为单条mRNA链编码的多抗原猴痘疫苗，用于预防猴痘。石药集团表示，该产品有望成为具备市场竞争力的猴痘疫苗，并进一步丰富公司mRNA疫苗创新产品管线。\\n\\n截至公告日，石药集团董事会由17名董事组成，包括11名执行董事和6名独立非执行董事。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658980734","title":"石药集团(01093)：SYS 6037注射液(猴痘m RNA疫苗)在美国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2658980734","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658980734?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:58","pubTimestamp":1786359500,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 公布，集团与中国科学院微生物研究所合作开发的预防用生物制品1类新药SYS 6037注射液已获得美国食品药品监督管理局批准，可在美国开展临床试验。猴痘由猴痘病毒引起，该病毒属于痘病毒科正痘病毒属。该产品有望成为具备市场竞争力的猴痘疫苗产品，进一步丰富集团m RNA疫苗创新产品管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478098.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226288253.USD","LU1807302812.USD","IBBJ","LU1813983027.USD","01093","MDTX","159646","PSYK","LU2039709279.SGD","RNA","BK4585","BK4588","LU1152091754.HKD","SG9999004220.SGD","LU0880133367.SGD","LU1226287875.USD","BK4505","LU0067412154.USD","LU1993786604.SGD","IE0009354923.USD","BK4139","LU1226287529.USD","IE00BZ08YT58.USD","BK1191","BK1521","BK1515","KURE","LU0072913022.USD","IBBQ","IE00B5MMRT66.SGD","LU0315179316.USD","LU1152091168.USD","IE00B543WZ88.USD","LU1226288170.HKD","IE0008369823.USD","IE00BZ08YS42.EUR","LU0326950275.SGD","HK0000165453.HKD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU0140636845.USD","LU0501845795.SGD","LU1226287792.SGD","BMED","LU1008478684.HKD","IE0008368742.USD","LU1328277881.USD","LU1951186391.HKD","LU0314109678.HKD","LU1960683339.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112361271","title":"异动解读｜石药集团盘中上涨4.43%，与阿斯利康合作持续深化","url":"https://stock-news.laohu8.com/highlight/detail?id=1112361271","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112361271?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:30","pubTimestamp":1786325448,"startTime":"0","endTime":"0","summary":"8月10日，石药集团盘中上涨4.43%，报9.085港元，成交额6039.15万港元。消息面上，公司近日密集释放利好。8月5日，石药集团宣布收到阿斯利康根据战略研发合作协议支付的1000万美元里程碑付款，表明临床前候选药物研发按计划推进；同日，双方签署合资合同，拟在石家庄成立合资公司建设新一代生物制剂生产基地。此外，8月4日公司与康宁杰瑞合作的安尼妥单抗联合多西他赛新辅助治疗上市申请获国家药监局受理并纳入优先审评。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657726255","title":"礼来上半年替尔泊肽大卖277亿美元；石药集团与阿斯利康成立合资公司丨医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2657726255","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657726255?lang=zh_cn&edition=full","pubTime":"2026-08-06 07:00","pubTimestamp":1785970805,"startTime":"0","endTime":"0","summary":"丨2026年8月6日星期四丨NO.1礼来：上半年替尔泊肽大卖277亿美元，中国区收入增长73%8月5日，礼来披露半年度业绩，公司上半年实现总营收427.73亿美元，同比增长49%。从地区分布来看，上半年美国市场收入265.32亿美元，同比增长37%，中国市场收入16.35亿美元，同比增长73%。上半年，礼来8款核心产品合计收入290.77亿美元，占总营收68%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608063832986566.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608063832986566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1770034418.SGD","LU0061475181.USD","LU0198837287.USD","LU2023250504.SGD","LU0072913022.USD","LU1629891620.HKD","LU2108987350.USD","RXL","LU0466842654.USD","IE00BJJMRY28.SGD","SG9999018865.SGD","LU0158827948.USD","LU2087625088.SGD","LU0943347566.SGD","SG9999014880.SGD","LU2264538146.SGD","IE0001KFT4U8.USD","IE00B4R5TH58.HKD","LU0109394709.USD","BK4581","LU1868837136.USD","BK4599","IE00BN29S564.USD","IE00BJLML261.HKD","LU2168564065.EUR","LU0354030511.USD","PPH","SGXZ57979304.SGD","LU2896262040.SGD","01093","LU1291159041.SGD","SG9999015986.USD","LU1280957306.USD","LU2552382132.HKD","IE0004445015.USD","LU0225283273.USD","LU0097036916.USD","LU0067412154.USD","LU2750360641.GBP","LU2168564149.EUR","LU2237443895.HKD","LU2213496289.HKD","LU0823416689.USD","LU2211815571.USD","BK4533","LU0708995401.HKD","LU2028103732.USD","LU0787776722.HKD","LU0122379950.USD","IE0008369823.USD","LU2552382215.SGD","LU1303224171.USD","IE00BKDWB100.SGD","LU1093756168.USD","IE00B7KXQ091.USD","LU0689472784.USD","LU1868836757.USD","LU2552382058.USD","LU1951186391.HKD","IE00BK4W5L77.USD","IE00BFTCPJ56.SGD","IXJ","LU2361044865.SGD","IE00B1BXHZ80.USD","TMED","LU0417517546.SGD","IE00B543WZ88.USD","LU1623119135.USD","LU2328871848.SGD","LU0315179316.USD","LU1226287529.USD","LU2023251221.USD","MEDX","LU1868836591.USD","LU1979441026.SGD","IE00BKPKM429.USD","LU1960683339.HKD","ILDR","06160","SGXZ51526630.SGD","LU0501845795.SGD","688235","BK4568","LU1145028129.USD","LU2462157665.USD","BK1515","LU0314109678.HKD","LU0823434740.USD","LU0174119429.USD","LU0326950275.SGD","LU0210536198.USD","SG9999015952.SGD","LU1226287875.USD","LU0588546209.SGD","SG9999014898.SGD","BK1588","LU0158827781.USD","SGXZ81514606.USD","LU2756315664.SGD","LU2237438978.USD","BK4007","LU0708994859.HKD","LU1814569148.SGD","LU2039709279.SGD","LU1232071149.USD","LU2023250330.USD","TRUH","LU0029864427.USD","LU0471298777.SGD","LU2361044949.HKD","LU2360106947.USD","CURE","JDOC","LU2746668461.USD","LU0323591593.USD","LU1813983027.USD","LU0320765059.SGD","LU0823434583.USD","XLV","LU1328277881.USD","LU1868837300.USD","IE00BJJMRZ35.SGD","BK1574","LU2324357040.USD","LU2168563687.JPY","IE00BZ08YT58.USD","LU2237443622.USD","BK1161","IE00B031HY20.USD","LU0354030438.USD","LU1251922891.USD","BK1500","LU1804176565.USD","WDNA","BK4588","LU1983299246.USD","IHE","LU2063271972.USD","SG9999014914.USD","LU1720051108.HKD","LU0820561818.USD","LU0882574139.USD","LU2491049909.HKD","LU2237443978.SGD","LU0140636845.USD","MHIP","688331","IE0009355771.USD","LU1712237335.SGD","LU0882574055.USD","IE00BJT1NW94.SGD","LU2089284900.SGD","LU0307460666.USD","LU1323610961.USD","AGNG","LU2461242641.AUD","LU0310800379.SGD","IYH","LU2456880835.USD","FHLC","LU1829250122.USD","IE00B4JS1V06.HKD","LU1226288170.HKD","LU1035775433.USD","AZN","LU0203201768.USD","SG9999001176.SGD","IE00B3T34201.USD","LU2237443549.SGD","LU0640476718.USD","LU0786609619.USD","LU0432979614.USD","LU2089984988.USD","LU1807302812.USD","LU1008478684.HKD","LU0109391861.USD","IE00B1XK9C88.USD","IE00BFSS8Q28.SGD","LU0106261372.USD","LU0385154629.USD","LU0683600562.USD","LU2746668974.SGD","LU0820562030.AUD","SG9999015945.SGD","LLII","LU2237443382.USD","LU0880133367.SGD","IE00B2B36J28.USD","LU2471134796.USD","LU0320765992.SGD","SG9999017495.SGD","LU1226288253.USD","LU1023059063.AUD","LU1064131342.USD","LU1988902786.USD","BK1521","IE0004445239.USD","LU0256863811.USD","GB00BDT5M118.USD","LU2491050071.SGD","LU2471134879.HKD","SG9999013999.USD","THNR","SGXZ31699556.SGD","LU2112291526.USD","LU0266013472.USD","LU2089283258.USD","LU0820561909.HKD","HK0000165453.HKD","LU1267930573.SGD","LU2756315318.SGD","LU0353189680.USD","LU2491050154.USD","SG9999004220.SGD","LU0964807845.USD","LU0353189763.USD","09995","ELIL","LU1868836914.USD","LU1720051017.SGD","FTXH","ONC","LLY","LU2471134952.CNY","BK4534","LU2265009873.SGD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU1719994722.HKD","LU1267930730.SGD","LU0672654240.SGD","LU1551013342.USD","LU2106854487.HKD","LU2462591350.SGD","LU1057294990.SGD","LU2602419157.SGD","LU1127390331.HKD","LU2471134523.USD","LU1969619763.USD","IE0008368742.USD","IE00B775H168.HKD","GDOC","SGXZ99366536.SGD","LU0238689110.USD","LU1548497426.USD","LU2750360997.AUD","SG9999015978.USD","LU0316494557.USD","LU0345770993.USD","IE00BJJMRX11.SGD","LU0456855351.SGD","LU1152091754.HKD","LU2236285917.USD","LU1152091168.USD","ELIS","LU1093756325.SGD","LU0096364046.USD","LU0133085943.USD","LU2237443465.HKD","LU2168564222.USD","HRTS","LU2271345857.HKD","LU0471298694.HKD","IE00BZ08YR35.GBP","BK4516","AZNH","LU0234572021.USD","SG9999001176.USD","LU0345770308.USD","IE00B5MMRT66.SGD","LU0256863902.USD","LLYZ","BK1583","LU0114720955.EUR","VHT","OZEM","MEDI","LU0058720904.USD","LLYX","BK1191","IE0005OL40V9.USD","CANC","LU1917777945.USD","IE00BK4W5M84.HKD","LU2468319806.SGD","LU2361045086.USD","PJP","LU2417539215.USD","LU1989771016.USD","LU1974910355.USD","LU0094547139.USD","LU0289739699.SGD","LU0128525929.USD","SG9999018857.SGD","LU1061106388.HKD","IE0002141913.USD","LU0079474960.USD","IE00BFSS7M15.SGD","LU0889565916.HKD","IE00BWXC8680.SGD","KURE","BK4585","LU2168564495.EUR","LU1551013425.SGD","LU1069344957.HKD","LU2111349929.HKD","LU1226287792.SGD","LU0006306889.USD","LU0203202063.USD","SG9999014906.USD","LU1366192091.USD","LU2357305700.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190783664","title":"石药集团（01093）宣布收到阿斯利康1000万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1190783664","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190783664?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:55","pubTimestamp":1785923744,"startTime":"0","endTime":"0","summary":"石药集团有限公司（01093）8月5日发布自愿公告称，公司已收到阿斯利康根据双方战略研发合作协议行使其中一个临床前候选药物（PCC）授权选择权而支付的1000万美元里程碑款项。\n该协议最早于2025年6月13日披露，双方围绕多个靶点共同发现并开发具多适应症潜力的口服小分子临床前候选药物。此次里程碑付款表明相关研发工作正在按计划推进。\n公告同时提醒，授权产品在后续开发、生产及商业化过程中仍存在不确定性，公司股东及潜在投资者在买卖公司证券时需审慎行事。石药集团表示，若合作取得重大进展，将及时作出进一步披露。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657108825","title":"石药集团：收到阿斯利康战略研发合作协议项下1000万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2657108825","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657108825?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:51","pubTimestamp":1785923509,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["SG9999004220.SGD","LU1152091168.USD","LU0314109678.HKD","IE0008369823.USD","BK1515","LU2039709279.SGD","01093","KURE","LU0140636845.USD","LU1226287792.SGD","IE00B543WZ88.USD","LU0067412154.USD","IE00B5MMRT66.SGD","LU0880133367.SGD","LU1226288170.HKD","LU1226287875.USD","LU1328277881.USD","LU0315179316.USD","BK1191","LU1152091754.HKD","LU1226287529.USD","LU1226288253.USD","LU1993786604.SGD","LU1008478684.HKD","LU1951186391.HKD","LU1813983027.USD","LU1807302812.USD","HK0000165453.HKD","IE00BZ08YR35.GBP","LU1960683339.HKD","IE00B031HY20.USD","IE00BZ08YS42.EUR","LU0072913022.USD","IE00BZ08YT58.USD","BK1521","IE0008368742.USD","LU0326950275.SGD","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189581382","title":"石药集团与阿斯利康签订合资合同　拟在石家庄建设生物制剂生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=1189581382","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189581382?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:48","pubTimestamp":1785919735,"startTime":"0","endTime":"0","summary":"01093 石药集团8月5日公告称，公司已与阿斯利康签署合资合同，双方计划在中国石家庄成立合资公司并建设新一代生物制剂生产基地，以深化战略合作。合资公司股权结构为石药集团持股51%，阿斯利康持股49%。石药集团董事会主席蔡东晨于2026年8月5日在香港签署公告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123247754","title":"石药集团联合研发安尼妥单抗组合新药获国家药监局受理并纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1123247754","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123247754?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:06","pubTimestamp":1785837984,"startTime":"0","endTime":"0","summary":"2026年8月4日，石药集团发布自愿公告称，其附属公司上海津曼特生物科技有限公司与江苏康宁杰瑞生物制药有限公司合作开发的安尼妥单抗联合石药集团自主研发的注射用多西他赛用作新辅助治疗的新药上市申请，已获国家药品监督管理局受理，并被纳入优先审评审批程序。近期，安尼妥单抗与HB1801已获国家药监局授予“突破性治疗”认定，用于一线不可切除或转移性HER2阳性乳腺癌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":0.0358},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1143},{"period":"6month","weight":-0.1227},{"period":"1year","weight":-0.1031},{"period":"ytd","weight":0.0522}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0507},{"period":"3month","weight":-0.036},{"period":"6month","weight":-0.0424},{"period":"1year","weight":0.0188},{"period":"ytd","weight":-0.0074}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事药品生产和销售的投资控股公司。该公司以“石药”品牌销售其产品。该公司包括四个业务部门：成药部门、抗生素（中间体及原料药）部门、维生素C（原料药）部门及咖啡因及其他（原料药）部门，分别从事生产及销售相关药品业务。该公司的成药包括抗生素、心脑血管用药、糖尿病用药、精神神经用药、抗肿瘤用药及中医药产品。该公司还通过其子公司从事提供药品研发服务及污水及药物副产品处理业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.009625},{"month":2,"riseRate":0.75,"avgChangeRate":0.094313},{"month":3,"riseRate":0.46875,"avgChangeRate":0.017543},{"month":4,"riseRate":0.59375,"avgChangeRate":0.057684},{"month":5,"riseRate":0.59375,"avgChangeRate":0.042479},{"month":6,"riseRate":0.3125,"avgChangeRate":0.001853},{"month":7,"riseRate":0.393939,"avgChangeRate":0.015989},{"month":8,"riseRate":0.454545,"avgChangeRate":0.009923},{"month":9,"riseRate":0.5,"avgChangeRate":0.000334},{"month":10,"riseRate":0.5625,"avgChangeRate":0.01001},{"month":11,"riseRate":0.46875,"avgChangeRate":0.006831},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013329}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}